Eli Lilly's obesity pill led to more than 12% weight loss in closely watched late-stage trial, paving way for approval
1. Eli Lilly's obesity pill shows a 12% body weight loss in trials. 2. Trial outcomes align with investor expectations but raise concerns over discontinuation. 3. Potential to dominate market among needle-averse patients is noted. 4. Launch of orforglipron is planned for 2026 after regulatory submissions. 5. Market for GLP-1 drugs could reach $150 billion by 2030.